Table 2.

Characteristics of patients with mild versus severe PIMS-TS/MIS(-C) of reported single cases (n = 138). Severe course was defined as presence of coronary dilatation/aneurysm, shock, death, need for mechanical ventilation, extracorporal membrane oxygenation (ECMO), renal replacement therapy, inotropes, or PICU admission. Abbreviations used: ECMO, extracorporal membrane oxygenation; IL, interleukin; IVIG, intravenous immunoglobulins; KD, Kawasaki disease; RRT, renal replacement therapy; WBC, white blood cells

	PIMS-TS/MIS(-C)
Variable	Severe course	Mild course
Count, n (%)	118 (100)	20 (100)
Age (year), median (IQR)	9 (6–12.7)	6.5 (3–9.75)
Male, n (%)	70 (59)	13 (65)
Symptoms, n (%)
Respiratory	56 (47)	12 (60)
Gastrointestinal	103 (87)	10 (50)
Cardiovascular	117 (99)	7 (35)
Shock	103 (87)	NA
Coronary dilatation	13 (11)	NA
Aneurysm formation	12 (10)	NA
Neurological	38 (32)	9 (45)
Dermatological	59 (50)	14 (70)
Fever ≥ 5 days	64 (54)	12 (60)
Complete KD	16 (14)	8 (40)
Incomplete KD	29 (25)	4 (20)
SARS-CoV-2, n (%)
RT-PCR-positive	54 (45)	9 (45)
Serology-positive	65 (55)	11 (55)
Critical care interventions, n (%)
PICU admission	64 (54)	NA
Inotropics	77 (65)	NA
Mechanical ventilation	35 (30)	NA
ECMO	5 (4)	NA
RRT	2 (2)	NA
Medical treatment, n (%)
IVIG once	90 (76)	14 (70)
IVIG multiple	9 (8)	2 (10)
Systemic corticoids	49 (42)	9 (45)
Anakinra	8 (7)	1 (5)
Tocilizumab	22 (19)	3 (15)
Infliximab	9 (8)	1 (5)
Laboratory markers, median (IQR)
WBC (/μl)	12,735 (8602.5–20,075)	14,950 (10025–18,827.5)
Lymphocytes (/μl)	800 (510–1190)	920 (700–1030)
Platelets (/μl)	181,000 (123,000–254,000)	121,000 (104000–151,000)
CRP (mg/l)	251 (183–328)	197 (132.25–258.7)
Ferritin (ng/ml)	966.5 (482.5–1569.25)	752.5 (343–1286.5)
IL-6 (pg/ml)	2197.15 (23.125–9927.5)	3689 (0.75–12,193.75)
Sodium (mmol/l)	130 (128–133)	132 (129.35–133)
d-Dimer (ng/ml)	3917 (2105.75–8218)	2818 (633.5–4379)
Troponin (ng/l)	2020.5 (111–9660)	193.5 (19–10,949.2)
Outcome, n (%)
Death	6 (5)	NA